Novel Radiolabeled TMTP1 for Long-Acting Hepatocellular Carcinoma Therapeutics.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00270
Abstract: Currently, the 5-year survival rate for patients with advanced hepatocellular carcinoma (HCC) is very low. Therefore, there is an urgent need to find new strategies for the treatment of HCC. TMTP1 (NVVRQ) is a tumor-homing… read more here.
Keywords: hepatocellular carcinoma; 177lu dota; tmtp1; dota tmtp1 ... See more keywords